Zimmer Biomet Holdings (ZBH) EBITDA (2009 - 2026)

Zimmer Biomet Holdings' EBITDA history runs 18 years deep, the most recent figure standing at $373.2 million for Q1 2026.

• On a quarterly basis, EBITDA rose 27.68% year-over-year to $373.2 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 10.14% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 14.59% from the prior year.
• EBITDA advanced to $373.2 million in Q1 2026 per ZBH's latest filing, from $154.5 million in the prior quarter.
• Across five years, EBITDA topped out at $389.0 million in Q4 2024 and bottomed at -$28.3 million in Q4 2022.
• The 5-year median for EBITDA is $292.3 million (2025), against an average of $278.3 million.
• Biggest YoY gain for EBITDA was 2581.08% in 2022; the steepest drop was 121.15% in 2022.
• Year by year, EBITDA stood at -$28.3 million in 2022, then soared by 1351.59% to $354.2 million in 2023, then grew by 9.82% to $389.0 million in 2024, then tumbled by 60.28% to $154.5 million in 2025, then soared by 141.55% to $373.2 million in 2026.
• Per Business Quant, the three latest ZBH EBITDA figures stand at $373.2 million (Q1 2026), $154.5 million (Q4 2025), and $351.3 million (Q3 2025).